Health

The Associated Press

partner publisher · 2.4M followers

Oklahoma Heart Institute Brings New National Cardiovascular Trials and Technologies to Patients Across the Region

BRENTWOOD, Tenn. & TULSA, Okla.--(BUSINESS WIRE)--Aug 11, 2026-- Oklahoma Heart Institute (OHI), part of Hillcrest HealthCare System and Ardent Health (NYSE: ARDT), is now the only site in Oklahoma and the surrounding region participating in several leading national cardiovascular trials – and recently became the first in the United States to use the next-generation Supira percutaneous left ventricular assist device (pVAD) as part of the SUPPORT II clinical trial . Through this research, OHI is expanding access to emerging therapies often available only at select academic medical centers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260811743593/en/ Kamran Muhammad, MD, FACC, FSCAI, of Oklahoma Heart Institute. The Supira pVAD is a minimally invasive heart pump that supports the left ventricle as it moves blood through the heart during high-risk stenting procedures. Its smaller profile is designed to safely extend these complex procedures to more patients who previously had limited options. The SUPPORT II trial is one of several national studies OHI is participating in to evaluate emerging technologies for patients with complex heart conditions. Structural heart specialist Kamran Muhammad, MD, FACC, FSCAI, has helped build OHI’s national profile – performing Tulsa’s first transcatheter aortic valve replacement (TAVR) procedure